The ATF7IP Knockout HT29 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population engineered for loss-of-function studies of the ATF7IP gene. This heterogeneous pool of HT29 cells carries targeted disruptions at the ATF7IP locus introduced via CRISPR/Cas9, providing a robust model to investigate ATF7IP-dependent functional processes without clonal selection. The polyclonal format offers an alternative to monoclonal knockout lines, capturing a broader representation of knockout effects across a cell population. This product is optimized for diverse assays exploring transcriptional regulation, epigenetic silencing, and chromatin remodeling within a human colorectal adenocarcinoma context.
The host cell line HT29 is a human colorectal adenocarcinoma model derived from a primary tumor (ATCC HTB-38). These cells form polarized epithelial monolayers and are extensively utilized in intestinal barrier function studies, colorectal cancer biology, and drug response profiling. HT29 cells retain characteristic features of intestinal epithelium, such as tight junction formation and mucin production, making them a relevant platform for dissecting mechanisms of epithelial homeostasis and neoplastic transformation. Their epithelial origin and colorectal cancer background render them particularly suitable for investigating epigenetic control of tumor cell behavior.
ATF7IP functions as a transcriptional coregulator that mediates epigenetic silencing through its association with the transcription factor ATF7 and the histone methyltransferase SETDB1. Upon binding ATF7, ATF7IP recruits SETDB1 to target gene promoters, catalyzing trimethylation of histone H3 at lysine 9 (H3K9me3). This modification facilitates chromatin compaction and transcriptional repression through interactions with heterochromatin protein 1 (HP1). The ATF7IP-SETDB1 complex cooperates with methyl-CpG-binding protein MBD1 and DNA methyltransferase DNMT1 to establish a repressive chromatin state. This pathway is essential for silencing retrotransposons and regulating genes involved in cell proliferation and differentiation, with upstream inputs from various transcription factors and downstream effects on H3K9me3-marked genomic regions.
In HT29 colorectal adenocarcinoma cells, ATF7IP-mediated H3K9me3 deposition contributes to the transformed phenotype. Knockout of ATF7IP permits dissection of heterochromatin dynamics on cancer cell properties, including proliferation, apoptosis, and epithelial barrier integrity. The model is valuable for studying how loss of ATF7IP-dependent silencing affects retrotransposon expression and chromatin accessibility, as well as cell migration and invasion processes relevant to metastasis. This system enables analysis of the interplay between epigenetic silencing and colorectal cancer progression.
This knockout cell population supports a spectrum of research applications, including chromatin immunoprecipitation followed by quantitative PCR (ChIP-qPCR) to assess H3K9me3 enrichment, RNA sequencing for transcriptome-wide analysis, and ATAC-seq for chromatin accessibility profiling. Protein-level validation can be performed via western blotting, while target gene expression is quantifiable by RT-qPCR. Functional assays such as cell proliferation, colony formation, apoptosis, and migration/invasion allow comprehensive phenotypic characterization. The model is well-suited for drug sensitivity testing and for exploring epigenetic therapies targeting heterochromatin regulators. For further technical information or to inquire about custom knockout products, please contact Ascent Research.
